ATE417622T1 - Regulation gastrointestinaler beweglichkeit - Google Patents

Regulation gastrointestinaler beweglichkeit

Info

Publication number
ATE417622T1
ATE417622T1 AT97938261T AT97938261T ATE417622T1 AT E417622 T1 ATE417622 T1 AT E417622T1 AT 97938261 T AT97938261 T AT 97938261T AT 97938261 T AT97938261 T AT 97938261T AT E417622 T1 ATE417622 T1 AT E417622T1
Authority
AT
Austria
Prior art keywords
pharmaceutically acceptable
regulation
gastrointestinal mobility
gastrointestinal
mobility
Prior art date
Application number
AT97938261T
Other languages
English (en)
Inventor
Andrew Young
Bronislava Gedulin
Nigel Beeley
Kathryn Prickett
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24790961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE417622(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE417622T1 publication Critical patent/ATE417622T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT97938261T 1996-08-08 1997-08-08 Regulation gastrointestinaler beweglichkeit ATE417622T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69495496A 1996-08-08 1996-08-08

Publications (1)

Publication Number Publication Date
ATE417622T1 true ATE417622T1 (de) 2009-01-15

Family

ID=24790961

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97938261T ATE417622T1 (de) 1996-08-08 1997-08-08 Regulation gastrointestinaler beweglichkeit
AT08016667T ATE493998T1 (de) 1996-08-08 1997-08-08 Pharmazeutische zusammensetzung mit einem exendin-4-peptid

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08016667T ATE493998T1 (de) 1996-08-08 1997-08-08 Pharmazeutische zusammensetzung mit einem exendin-4-peptid

Country Status (11)

Country Link
US (6) US6858576B1 (de)
EP (2) EP0966297B2 (de)
JP (2) JP2001501593A (de)
AT (2) ATE417622T1 (de)
AU (1) AU4063697A (de)
CA (1) CA2262647C (de)
DE (2) DE69739172D1 (de)
DK (2) DK0966297T4 (de)
ES (2) ES2319936T5 (de)
PT (1) PT966297E (de)
WO (1) WO1998005351A1 (de)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600457B1 (ko) * 1996-06-05 2006-07-13 로셰 디아그노스틱스 게엠베하 엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ES2425559T5 (es) 1997-01-07 2018-02-02 Amylin Pharmaceuticals, Llc Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas
EP1938831A1 (de) * 1997-08-08 2008-07-02 Amylin Pharmaceuticals, Inc. Neue Exendinagonist-Verbindungen
AU749914B2 (en) * 1997-08-08 2002-07-04 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
BR9815670A (pt) 1997-11-14 2000-10-17 Amylin Pharmaceuticals Inc Compostos agonistas de exendina
EP1941900A1 (de) * 1997-11-14 2008-07-09 Amylin Pharmaceuticals, Inc. Neue Exendinagonist-Verbindungen
EP1938830A1 (de) * 1997-11-14 2008-07-02 Amylin Pharmaceuticals, Inc. Neue Exendinagonist-Verbindungen
AU2006225176B2 (en) * 1997-11-14 2009-01-08 Amylin Pharmaceuticals, Llc Novel exendin agonist compounds
AU2003200129B2 (en) * 1997-11-14 2006-06-22 Amylin Pharmaceuticals, Llc Novel Exendin Agonist Compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
JP2001523688A (ja) * 1997-11-14 2001-11-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規エキセンジン・アゴニスト化合物
KR100637433B1 (ko) 2004-05-24 2006-10-20 삼성에스디아이 주식회사 발광 표시 장치
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
JP4677095B2 (ja) * 1998-02-13 2011-04-27 アミリン・ファーマシューティカルズ，インコーポレイテッド エキセンジンおよびｇｌｐ−１の変力および利尿効果
WO1999043708A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
CA2339326A1 (en) * 1998-08-10 2000-02-24 Josephine Egan Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
ES2278589T3 (es) 1999-01-14 2007-08-16 Amylin Pharmaceuticals, Inc. Excendinas destinadas a la inhibicion de glucagon.
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
NZ514916A (en) * 1999-04-30 2004-06-25 Amylin Pharmaceuticals Inc Exendins and exendin agonists linked to polyethylene glycol polymers
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
WO2000069911A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (de) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptide zur Senkung des Blutglukosespiegels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20030022840A1 (en) * 2000-02-18 2003-01-30 Michiko Kishino Drugs for ameliorating impaired glucose tolerance
US7399304B2 (en) * 2000-03-03 2008-07-15 C.R. Bard, Inc. Endoscopic tissue apposition device with multiple suction ports
US7220266B2 (en) * 2000-05-19 2007-05-22 C. R. Bard, Inc. Tissue capturing and suturing device and method
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
US20050148497A1 (en) 2002-02-20 2005-07-07 Khan Mohammed A. Method for administering glp-1 molecules
DE60327771D1 (de) 2002-07-04 2009-07-09 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
MXPA05003335A (es) 2002-10-02 2005-07-05 Zealand Pharma As Compuestos de exendina-4 estabilizados.
MXPA05004202A (es) * 2002-10-22 2005-09-20 Waratah Pharmaceuticals Inc Tratamiento de la diabetes.
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1687019B1 (de) 2003-11-20 2017-11-22 Novo Nordisk A/S Für die herstellung und verwendung in injektionsvorrichtungen optimale propylenglykol enhaltende peptidformulierungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
RU2006131046A (ru) * 2004-01-30 2008-03-10 Уэрейта Фармасьютикалз, Инк. (Ca) Совместное применение агониста glp-1 и соединений гастрина
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005103087A1 (en) 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
US8172857B2 (en) 2004-08-27 2012-05-08 Davol, Inc. Endoscopic tissue apposition device and method of use
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
KR101123549B1 (ko) 2004-11-01 2012-04-18 아밀린 파마슈티칼스, 인크. 비만 및 관련 장애의 치료
SG157423A1 (en) 2004-12-02 2009-12-29 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
EP1841448A2 (de) * 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmazeutische zusammensetzungen und vefahren zur wiederherstellung der betazellmasse und funktion
WO2006074600A1 (fr) 2005-01-14 2006-07-20 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Exendines modifiees et utilisations correspondantes
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP2392595A1 (de) 2005-02-11 2011-12-07 Amylin Pharmaceuticals Inc. GIP-Analog und Hybridpolypeptide mit auswählbaren Eigenschaften
CN100429227C (zh) * 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin4多肽片段
EP1922336B1 (de) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybridpolypeptide mit auswählbaren eigenschaften
NZ566763A (en) 2005-08-19 2011-06-30 Amylin Pharmaceuticals Inc Exendin-4 for treating diabetes, obesity and reducing body weight
ES2462117T3 (es) * 2005-09-06 2014-05-22 Oramed Pharmaceuticals Inc. Métodos y composiciones para la administración oral de proteínas
EP1937297A2 (de) * 2005-09-08 2008-07-02 Gastrotech Pharma A/S Verwendung eines glp-1-moleküls zur behandlung von biliärer dyskinesie und/oder biliären schmerzen/beschwerden
ATE448247T1 (de) * 2005-09-22 2009-11-15 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
EP1854455B1 (de) * 2006-05-10 2009-10-07 Biocompatibles UK Limited GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
MX2009001066A (es) * 2006-07-24 2009-02-05 Biorexis Pharmaceutical Corp Proteinas de fusion de exendina.
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
JO2945B1 (en) * 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
EP1972349A1 (de) * 2007-03-21 2008-09-24 Biocompatibles UK Limited Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
EP1975176A1 (de) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US8236760B2 (en) * 2007-04-27 2012-08-07 Cedars-Sinsai Medical Center Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
WO2009033687A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Spantide ii and bfgf (119-126) for therapeutic applications
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
BRPI0907077A2 (pt) * 2008-03-26 2016-07-26 Oramed Ltd métodos e composições para administração oral de proteínas
BRPI0909397A2 (pt) 2008-03-31 2015-12-15 Glaxo Group Ltd composição, uso de uma composição, formulação, dispositivo de liberação, ácido nucléico, vetor, célula hospedeira, e, métodos para produzir um polipeptídeo de fusão
CN102026646A (zh) 2008-05-05 2011-04-20 奥拉姆德有限公司 用于口服给予艾塞那肽的方法和组合物
EP2303313B1 (de) 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendine zur senkung der cholesterin- und triglyceridwerte
CA2731236A1 (en) * 2008-07-21 2010-01-28 Transpharma Medical Ltd. Transdermal system for extended delivery of incretins and incretin mimetic peptides
ES2823233T3 (es) 2008-08-18 2021-05-06 Entera Bio Ltd Métodos y composiciones para la administración oral de proteínas
US8895033B2 (en) 2008-09-04 2014-11-25 Amylin Pharmaceuticals, Llc Sustained release formulations using non-aqueous carriers
EP2163243A1 (de) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
SI2349324T1 (en) 2008-10-17 2018-01-31 Sanofi-Aventis Deutschland Gmbh The combination of insulin and agonist GLP-1
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DK2373681T3 (en) 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
EP2411054A2 (de) 2009-03-27 2012-02-01 Glaxo Group Limited Arzneifusionen und konjugate
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
EP2435061A4 (de) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc Schlaffördernde glp-1-rezeptor-agonistenverbindungen
KR101321461B1 (ko) * 2009-08-10 2013-10-29 아크레이 가부시키가이샤 췌도 이미징용 분자 프로브 및 그 전구체, 및 그들의 사용
KR20150006083A (ko) 2009-09-28 2015-01-15 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
JP2013506628A (ja) 2009-09-30 2013-02-28 グラクソ グループ リミテッド 延長された半減期を有する薬物融合物及びコンジュゲート
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
DE102010011919A1 (de) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
AR078973A1 (es) 2009-11-13 2011-12-14 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
EP2563808B1 (de) 2010-04-27 2016-12-07 Zealand Pharma A/S Peptidkonjugate aus glp-1-rezeptoragonisten und gastrin sowie ihre verwendung
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
SI2611458T1 (sl) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
JP2014504588A (ja) 2010-12-22 2014-02-24 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP2014521594A (ja) 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニーＡｍｙｌｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｌｃ 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
MX370264B (es) 2011-08-29 2019-12-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
SI2763690T1 (sl) 2011-10-04 2016-03-31 Sanofi-Aventis Deutschland Gmbh Liksisenatid za uporabo pri zdravljenju stenoze in/ali obstrukcije v sistemu vodov trebušne slinavke
WO2013050378A1 (en) 2011-10-04 2013-04-11 Sanofi-Aventis Deutschland Gmbh Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
WO2013064669A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
JP6174601B2 (ja) 2012-01-03 2017-08-02 オラムド エルティーディー． 糖尿病を処置するための方法及び組成物
US10342764B2 (en) 2012-02-01 2019-07-09 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
CA2873536A1 (en) 2012-05-16 2013-11-21 Glaxo Group Limited Polypeptide loaded poca nanoparticles for oral administration
CN107739409A (zh) 2012-05-18 2018-02-27 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
WO2013186240A2 (en) 2012-06-14 2013-12-19 Sanofi Exendin-4 peptide analogues
ES2620111T3 (es) 2012-07-23 2017-06-27 Zealand Pharma A/S Análogos de glucagón
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE038748T2 (hu) 2012-12-21 2018-11-28 Sanofi Sa Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
AU2014261111B2 (en) 2013-05-02 2017-03-16 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TWI666220B (zh) 2013-10-17 2019-07-21 丹麥商西蘭製藥公司 醯化升糖素類似物
MX369770B (es) 2013-11-06 2019-11-21 Zealand Pharma As Compuestos agonistas triples de glucagón-glp-1-gip.
KR102310389B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
AU2014359894B2 (en) 2013-12-06 2020-09-17 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3080150B1 (de) 2013-12-13 2018-08-01 Sanofi Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (de) 2013-12-13 2016-10-19 Sanofi Duale glp-1-/glucagon-rezeptoragonisten
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
AU2015205621A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3212218B1 (de) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip-agonisten-verbindungen und -verfahren
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
EP3297653B1 (de) 2015-05-22 2021-09-15 The Board of Trustees of the Leland Stanford Junior University Behandlung von post-bariatrischer hypoglykämie mit glp-1-antagonisten
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR20180084782A (ko) 2015-10-14 2018-07-25 엑스-써마 인코포레이티드 얼음 결정 형성을 감소시키기 위한 조성물 및 방법
WO2017112824A2 (en) 2015-12-23 2017-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017178829A1 (en) * 2016-04-15 2017-10-19 Imperial Innovations Limited Peptide analogues
EP3733694A1 (de) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3515408A1 (de) 2016-09-23 2019-07-31 Delpor, Inc. Stabile zusammensetzungen für inkretin-mimetische verbindungen
CN110267648A (zh) 2016-11-21 2019-09-20 艾格尔峰生物制药有限公司 毒蜥外泌肽(9-39)的缓冲制剂
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
BR112019010624A2 (pt) 2016-12-09 2019-10-22 Zealand Pharma As agonistas duplos de glp-1/glp-2 acilados e composição
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JP7237853B2 (ja) 2017-06-20 2023-03-13 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対する結合タンパク質をｇｌｐ－１アゴニストと組み合わせて使用する、代謝障害の治療方法又は寛解方法
KR20200044016A (ko) 2017-08-24 2020-04-28 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
BR112020020652A2 (pt) 2018-04-10 2021-03-02 Sanofi-Aventis Deutschland Gmbh método para clivagem de peptídeos ligados à fase sólida a partir da fase sólida
EP3774838B1 (de) 2018-04-10 2022-08-10 Sanofi-Aventis Deutschland GmbH Lixisenatidsynthese mit verkappung
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
JP2022523972A (ja) 2019-03-08 2022-04-27 アムジエン・インコーポレーテツド 増殖分化因子１５併用療法
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862301A (en) * 1973-06-18 1975-01-21 Stanley M Chernish Glucagon as a diagnostic aid in gastrointestinal radiology
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5130133A (en) * 1990-09-28 1992-07-14 The Procter & Gamble Company Plant extracts as mucosal-protective agents
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
PT717635E (pt) * 1993-09-07 2001-04-30 Amylin Pharmaceuticals Inc Metodos para regulacao da motilidade gastrintestinal
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0662514A1 (de) 1994-01-07 1995-07-12 Ciba-Geigy Ag Hirustasin, ein Serinprotease-Inhibitor des Antistasintyps aus Hiruda
EP0788371A1 (de) 1994-08-26 1997-08-13 LEE, Nancy M. Analgetisches verfahren mit n-terminal verkürzten dynorphinanaloga
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5737735A (en) 1996-05-14 1998-04-07 Resolve 2000, Inc. Method and apparatus for recording and reading date data having coexisting formats
KR100600457B1 (ko) 1996-06-05 2006-07-13 로셰 디아그노스틱스 게엠베하 엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
ES2425559T5 (es) 1997-01-07 2018-02-02 Amylin Pharmaceuticals, Llc Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US5846937A (en) * 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
AU749914B2 (en) 1997-08-08 2002-07-04 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6442619B1 (en) 1997-12-31 2002-08-27 Alcatel Usa Sourcing, L.P. Software architecture for message processing in a distributed architecture computing system
JP4353544B2 (ja) 1998-01-09 2009-10-28 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリン作動薬ペプチド用製剤
DE29802348U1 (de) 1998-02-11 1998-04-23 Siemens Ag Elektromagnetischer Stromauslöser für einen elektrischen Schutzschalter
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
JP4072319B2 (ja) 1998-03-13 2008-04-09 ノヴォ ノルディスク アクティーゼルスカブ 安定化水溶性ペプチド溶液
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
ES2278589T3 (es) 1999-01-14 2007-08-16 Amylin Pharmaceuticals, Inc. Excendinas destinadas a la inhibicion de glucagon.
WO2003102136A2 (en) * 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
US6782700B1 (en) * 2004-02-24 2004-08-31 Sunpower, Inc. Transient temperature control system and method for preventing destructive collisions in free piston machines

Also Published As

Publication number Publication date
US7521423B2 (en) 2009-04-21
DK0966297T3 (da) 2009-03-23
PT966297E (pt) 2009-03-18
CA2262647C (en) 2007-12-04
US20040266692A1 (en) 2004-12-30
EP0966297A4 (de) 2001-07-11
AU4063697A (en) 1998-02-25
DK0966297T4 (da) 2013-03-18
US20130331322A1 (en) 2013-12-12
EP0966297A1 (de) 1999-12-29
EP2016950A1 (de) 2009-01-21
US8026210B2 (en) 2011-09-27
US20120004168A1 (en) 2012-01-05
DK2016950T3 (da) 2011-04-04
US6858576B1 (en) 2005-02-22
ES2319936T3 (es) 2009-05-14
US20150080307A1 (en) 2015-03-19
JP2001501593A (ja) 2001-02-06
WO1998005351A1 (en) 1998-02-12
DE69740096D1 (de) 2011-02-17
CA2262647A1 (en) 1998-02-12
EP2016950A8 (de) 2009-07-01
DE69739172D1 (de) 2009-01-29
EP2016950B1 (de) 2011-01-05
ES2319936T5 (es) 2013-06-24
US20090163423A1 (en) 2009-06-25
JP2008044964A (ja) 2008-02-28
EP0966297B1 (de) 2008-12-17
ES2359031T3 (es) 2011-05-17
EP0966297B2 (de) 2013-02-27
ATE493998T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
ATE417622T1 (de) Regulation gastrointestinaler beweglichkeit
LU91225I2 (fr) Plenaxis
IL109403A0 (en) Oral drug delivery compositions and methods
HK1030768A1 (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents.
ATE306906T1 (de) Verzögerte freisetzung von peptiden aus pharmazeutischen zusammensetzungen
DE69417252T2 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
ATE187740T1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
AU5446590A (en) Drugs (calcitonin gene-related peptides) for treating erectile dysfunctions
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
TR199501630A2 (tr) Peptid p277 benzerleri ve diagnoz ve dibetlerin'lerin tedavisi icin onlari iceren kompozisyonlar.
NZ504771A (en) IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
NO302472B1 (no) Sulfonylureaforbindelse, farmasöytisk formulering og anvendelse derav
ATE546461T1 (de) Gnrh analog von nicht-säugertieren und verwendung zur regulierung der fruchtbarkeit und der schwangerschaft
PT655244E (pt) Composicao a base de acidos aminados para o tratamento de infeccoes
IL105569A (en) Pharmaceutical compositions containing remacemide for the treatment of parkinson's disease
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
IT1254191B (it) Composizioni farmaceutiche stabili per la somministrazione orale di calcitonina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0966297

Country of ref document: EP